<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03266185</url>
  </required_header>
  <id_info>
    <org_study_id>NL61964.058.17</org_study_id>
    <nct_id>NCT03266185</nct_id>
  </id_info>
  <brief_title>Shorter Scalp Cooling Time in Paclitaxel</brief_title>
  <acronym>COP</acronym>
  <official_title>Prospective, Multi-centre Trial to Evaluate Effectiveness of 45-min and 20-min Post-infusion Cooling Time for Patients Treated With Scalp Cooling to Prevent Paclitaxel-induced Alopecia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-induced alopecia (CIA) is one of the most distressing side effects for patients.&#xD;
      Scalp cooling can prevent or minimise CIA in approximately half of all patients, depending on&#xD;
      many factors, e.g. type and dosage of chemotherapy. High rates of success are seen in&#xD;
      patients treated with taxanes, up to 80-90%. Previous research has shown comparable results&#xD;
      of scalp cooling in docetaxel-treated patients when shortening the post-infusion cooling time&#xD;
      (PICT) from the initial standard of 90 minutes to 45- and 20 minutes. A shorter PICT is an&#xD;
      advantage for both the patient, who can spend less time in the hospital, as well for the&#xD;
      logistics at oncological departments. Paclitaxel and docetaxel are both classical taxanes,&#xD;
      that share similar mechanisms of action and have comparable plasma terminal half-life times,&#xD;
      therefore it seems plausible that the PICT can be shortened for paclitaxel-treated patients&#xD;
      as well.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">August 28, 2020</completion_date>
  <primary_completion_date type="Actual">August 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of scalp cooling in patients treated with paclitaxel-containing chemotherapy with a 45- and 20-minutes post-infusion cooling time, defined by the patient's self-determined need to wear a wig or other head covering</measure>
    <time_frame>up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the degree of chemotherapy-induced alopecia (CIA), assessed with the DEAN scale for assessment of hair loss</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the grade of chemotherapy-induced alopecia (CIA), according to NCI-CTCAEv4.03</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the tolerance of scalp cooling, assessed by a (self-adapted) visual analogue scale (VAS)</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the added value of scalp cooling for weekly paclitaxel; what is the incidence of severe alopecia with and without scalp cooling</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the amount of distress experienced by CIA in patients, assessed with the chemotherapy-induced alopecia distress scale (CADS)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Neoplasm Malignant</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>45-minutes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45-minutes post-infusion cooling time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20-minutes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20-minutes post-infusion cooling time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No scalp cooling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Shorter PICT</intervention_name>
    <description>Shorter post-infusion cooling time</description>
    <arm_group_label>20-minutes</arm_group_label>
    <arm_group_label>45-minutes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving weekly-administered paclitaxel-containing chemotherapy (minimal 3&#xD;
             planned administrations) in a dose of 80-90 mg/m2 Paclitaxel monotherapy, Paclitaxel&#xD;
             in combination with carboplatin, Paclitaxel in combination with monoclonal antibodies:&#xD;
             Bevacizumab or Trastuzumab&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Survival expectation must be &gt; 3 months&#xD;
&#xD;
          -  Written informed consent according to the local Ethics Committee requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with paclitaxel in sequential schemes with other alopecia inducing agents&#xD;
             such as paclitaxel monotherapy after adriamycin, cyclophosphamide (AC) or paclitaxel&#xD;
             monotherapy after 5-fluouracil, epirubicin, cyclophosphamide (FEC) treatment&#xD;
&#xD;
          -  Alopecia before the start of the study&#xD;
&#xD;
          -  Rare cold-related disorders: Cold sensitivity, Cold agglutinin disease,&#xD;
             Cryoglobulinaemia, Cryofibrinogenaemia, Cold posttraumatic dystrophy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 26, 2017</study_first_submitted>
  <study_first_submitted_qc>August 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>J.R. Kroep</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>paclitaxel-containing chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

